ASHLEE SPARKS: Open Payments
NPI 1841905007 · BELLMEAD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,339 in 78 payments from 19 companies in 2025. Trend: 2023 $1,040 · 2024 $1,209 · 2025 $1,339
Food & beverage: $1,339
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $290 |
| Sumitomo Pharma America, Inc. | 2 | $188 |
| Novo Nordisk Inc | 8 | $149 |
| AstraZeneca Pharmaceuticals LP | 7 | $131 |
| Lilly USA, LLC | 6 | $96 |
| Phathom Pharmaceuticals, Inc. | 11 | $76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $73 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Exact Sciences Corporation | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
Products named: GEMTESA, UBRELVY, JARDIANCE, MOUNJARO, VOQUEZNA, QULIPTA, FARXIGA, VRAYLAR.
Industry payments across TX — which companies pay providers there.
